Skip to content
eleva logo — Next level medicine with ease. Powered by moss.

eleva

Next level medicine with ease. Powered by moss.

Founded 1999 Germany Freiburg, Germany 87 employees Venture round Total: $60.00M Biopharma, Biotechnology +1

General Information

Company Name eleva
Founded Year 1999
Location Germany Freiburg, Germany
Employees 87
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Venture round
Business Model B2B, Platform
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with eleva. To contact eleva, visit elevabiologics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does eleva compare?

A PDF of eleva and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting eleva soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About eleva

Eleva, a pioneering biopharmaceutical firm headquartered in Germany, is committed to transforming the landscape of medicine through its innovative, moss-based technology. Founded in 1999, Eleva is on the cutting edge of biotechnology, focusing on the discovery and development of previously inaccessible biological therapeutics.

Their flagship clinical-stage program, Factor H (CPV-104), promises to unlock new therapeutic possibilities for patients with severe kidney disorders, dry AMD, and other complement-driven diseases. By targeting precision complement modulation, Eleva is set to redefine treatment paradigms in these areas.

The company’s last investment was a significant €60.00M venture round on 06 January 2021, led by Zukunftsfonds Heilbronn. This positions Eleva strongly for continued growth and expansion of its already promising drug pipeline.

Business keywords: Biopharmaceuticals, Clinical-stage Therapeutics, Precision Complement Modulation, Kidney Disorders, Dry AMD, Complement-driven Diseases, Moss-based Technology, Biologics Production, Antibodies, Replacement Enzymes, Fusion Toxins, Rare Diseases Treatment, Renal Diseases, Clinical Development

Services & Products

Development of biologics
Clinical trials for new therapies
Biotechnology platform development

Target Customers

Patients with complement disorders Healthcare providers Pharmaceutical partnerships Research institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €60.00M 1
Zukunftsfonds Heilbronn
06 Jan 2021

eleva Alternatives & Competitors

View All Alternatives
eleva vs

Building a leading biotech company focused in severe autoimmune diseases.

Post-IPO Equity
124 employees
Biopharma, Biotechnology
eleva vs

Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders

Post-IPO Equity
13 employees
Biotechnology, Health and Wellness
eleva vs
KAMADA
KAMADA Israel

Specialty Plasma-Derived Therapeutics

Post-IPO Equity
318 employees
Biopharma, Biotechnology

FAQ About eleva

Next level medicine with ease. Powered by moss.
eleva was founded in 1999.
eleva is headquartered in Freiburg, Germany.
eleva operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on Biopharmaceuticals, Clinical-stage Therapeutics, Precision Complement Modulation and Kidney Disorders. Its customers include Patients with complement disorders, Healthcare providers and Pharmaceutical partnerships.
eleva has a B2B and Platform business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
eleva has approximately 87 employees.
eleva has completed 1 funding round, raising a total of $60.00M. The latest funding stage is Venture round.
eleva offers: Development of biologics, Clinical trials for new therapies, Biotechnology platform development.
Top alternatives and competitors to eleva include Dianthus Therapeutics, Inc., Allena Pharmaceuticals, Inc., KAMADA, Angitia Biopharmaceuticals, Visterra Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
eleva and Dianthus Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for eleva, https://www.bouncewatch.com/company/eleva, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout